Cybin publishes corporate presentation on development of serotonergic agonists for depression, anxiety
CYBN•Cash position and financing
Cybin said its cash position was US$157.3 million as of March 31, 2026, and that it completed a US$50 million underwritten offering in June 2026.
Corporate presentation highlights pipeline progress
Cybin highlighted HLP003, an oral deuterated serotonergic agonist in Phase 3 for adjunctive major depressive disorder with FDA Breakthrough Therapy Designation.
Phase 3 APPROACH topline data are targeted for Q4 2026; Phase 3 dosing is underway; Phase 2 showed a 23-point MADRS reduction at 12 months.
The program update cited a 100% response rate and 71% remission at 12 months for patients receiving two 16 mg doses in Phase 2 follow-up.
Second clinical asset in generalized anxiety disorder
The company said its second clinical asset, HLP004, an intramuscular deuterated serotonergic agonist for generalized anxiety disorder, completed a Phase 2 signal-finding study.
